anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention is based on the recording of raw data sets by means of a medical imaging device using a measurement protocol. Furthermore, the raw data set and the measurement protocol are transmitted from the medical device to the reconstruction unit. Furthermore, an at least two-dimensional image data record is calculated from the raw data record by means of a reconstruction unit. Furthermore, display parameters are called up by the reconstruction unit, wherein the display parameters are associated with the measurement protocol and wherein the display parameters define a first projection method for the image data set. Furthermore, the image data set and the display parameters are transmitted from the reconstruction unit to the display unit, wherein the reconstruction unit and the display unit are spatially separated. Furthermore, a first projection data set is determined by means of the display unit by applying a first projection method to the image data set.
Recent advances in computed tomography have resulted in new applications of CT scans in musculoskeletal imaging. Dual-energy CT technology involves the acquisition of data at high and low kilovolts, allowing differentiation and quantification of materials with different X-ray absorption. Newer CT scanners with a variety of post-processing options allow interesting applications of dual-energy CT in musculoskeletal and trauma imaging. This article provides an overview of the basic principles and physics of DECT. We review applications of DECT in the evaluation of the acute painful joint with suspicion of gout, metal artefact reduction in the prosthetic joint and in imaging of patients following major trauma. We present a review of literature and case examples to illustrate the strengths and limitations of this modality in the diagnosis of acute musculoskeletal conditions.
Widespread metastasis is the primary reason for the high mortality associated with ovarian cancer (OC), and effective targeted therapy for tumor aggressiveness is still insufficient in clinical practice. Therefore, it is urgent to find new targets to improve prognosis of patients. PDE4A is a cyclic nucleotide phosphodiesterase that plays a crucial role in the occurrence and development in various malignancies. Our study firstly reported the function of PDE4A in OC. Expression of PDE4A was validated through bioinformatics analysis, RT-qPCR, Western blot, and immunohistochemistry. Additionally, its impact on cell growth and motility was assessed via in vitro and in vivo experiments. PDE4A was downregulated in OC tissues compared with normal tissues and low PDE4A expression was correlated with poor clinical outcomes in OC patients. The knockdown of PDE4A significantly promoted the proliferation, migration and invasion of OC cells while overexpression of PDE4A resulted in the opposite effect. Furthermore, smaller and fewer tumor metastatic foci were observed in mice bearing PDE4A-overexpressing OVCAR3 cells. Mechanistically, downregulation of PDE4A expression can induce epithelial-mesenchymal transition (EMT) and nuclear translocation of Snail, which suggests that PDE4A plays a pivotal role in suppressing OC progression. Notably, Rolipram, the PDE4 inhibitor, mirrored the effects observed with PDE4A deletion. In summary, the downregulation of PDE4A appears to facilitate OC progression by modulating the Snail/EMT pathway, underscoring the potential of PDE4A as a therapeutic target against ovarian cancer metastasis.
In addition to the routine follow-ups and trainings that the pregnant women in the intervention group can receive from the hospital, they will be included in the "Attachment Based Support Program". Within the scope of the 1st stage of this support; A mobile application. There are 12 videos on connecting in the mobile application. These videos were shot by the researcher in a professional studio. 22nd-26th of pregnancy. The participants included in the study during the weeks of participation installed this mobile application on their phones during participation. It was requested to complete watching the videos by 36 weeks. In the second phase of Attachment-Based Support, breastfeeding and skin-to-skin contact support are provided to mothers on postpartum day 0.
NEW MATERIAL:A peptide containing an amino acid sequence, having an activity inhibiting the conjugation between a human intercellular adhesive molecule-1 (ICAM-1) and a human lymphocytic function-relating antigen-1 (LFA-1), and represented by the formula, etc. EXAMPLE:A therapeutic agent for preventing denial reactions in organ transplantation and for treating inflammatory diseases such as allergic diseases and autommune diseases. USE:For example, a mouse is immunized with a human colon cancer cell line BM 314 stimulated with gamma-interferon. Splenic cells, etc., are collected from the mouse, fused with myeloma cells and subsequently selectively cultured in a HAT medium to prepare hybridomas. The hydridomas are screened, and a positive clone is selected. All RNAs are extracted, and cDNA coding the V region of an antibody is separated from the RNAs. The obtained cDNA is tracted with an enzyme, bound to a plasmid vector, and inserted into a host to transform the host, which is cultured to provide the peptide containing the amino acid sequence of the formula, etc.
Maternal obesity is associated with an increased risk of psychiatric disorders such as anxiety, depression, schizophrenia and autism spectrum disorder in the offspring. While numerous studies focus on preventive measures targeting the mothers, only a limited number provide practical approaches for addressing the damages once they are already established. We have recently demonstrated the interplay between maternal obesity and treatment with cannabidiol (CBD) on hypothalamic inflammation and metabolic disturbances, however, little is known about this relationship on behavioral manifestations and neurochemical imbalances in other brain regions. Therefore, here we tested whether CBD treatment could mitigate anxiety-like and social behavioral alterations, as well as neurochemical disruptions in both male and female offspring of obese dams. Female Wistar rats were fed a cafeteria diet for 12 weeks prior to mating, and during gestation and lactation. Offspring received CBD (50 mg/kg) from weaning for 3 weeks. Behavioral tests assessed anxiety-like manifestations and social behavior, while neuroinflammatory and neurochemical markers were evaluated in the prefrontal cortex (PFC) and hippocampus. CBD treatment attenuated maternal obesity-induced anxiety-like and social behavioral alterations, followed by rescuing effects on imbalanced neurotransmitter and endocannabinoid concentrations and altered expression of glial markers, CB1, oxytocin and dopamine receptors, with important differences between sexes. Overall, the findings of this study provide insight into the signaling pathways for the therapeutic benefits of CBD on neuroinflammation and neurochemical imbalances caused by perinatal maternal obesity in the PFC and the hippocampus, which translates into the behavioral manifestations, highlighting the sexual dimorphism encompassing both the transgenerational effect of obesity and the endocannabinoid system.
Patients in the control arm will receive, in a blinded fashion, 160mg of the placebo orally four times a day for the first five postoperative days. The placebo will be prepared by pharmacy to be identical to the test drug formulation except for being pharmacologically inert. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland) .
Treatment of soft tissue wounds with bone or tendon exposure remains a tough clinical challenge for surgeons. The current clinical approaches include various types of flap reconstruction and artificial dermis grafting as well as negative pressure wound therapy (NPWT), which are time-consuming and often result in graft failure or significant scarring. Concentrated growth factor (CGF) is a novel blood extract that contains many growth factors, platelets and fibrin to promote an orderly healing process. However, few reports have focused on wounds with bone or tendon exposure. We present a limited series and two specific cases of skin wound with bone or tendon exposed that received surgical debridement followed by CGF treatment. CGF appeared to facilitate wound closure effectively and also reduced scar formation. Our findings provide a novel therapeutic option for refractory wounds with bone or tendon exposure.
The present invention provides a compound preparation capable of consuming fat, reducing weight and shaping figure, and a preparation method thereof, which relates to a compound preparation capable of promoting fat combustion in human bodies, reducing weight and shaping figure. The preparation is prepared from aloes, refined konjaku flour, L-carnitine, rhizoma atractylodis macrocephalae, lotus leaves and semen cassiae. The preparation method specifically comprises the following process flow: processing the qualified lotus leaves, the semen cassiae and the rhizoma atractylodis macrocephalae, decocting in a decoction pot according to needed amount and filtering; concentrating purified filtering liquid to be with a relative density of 1.25 (+/-)0.05; concentrating medicine juice into clear paste and drying and sterilizing the clear paste so as to obtain the extract of the traditional Chinese medicine; crushing and sieving the aloes, mixing the ingredients according to proportions, drying and sterilizing mixed granules and packaging the mixed granules so as to obtain a product. The preparation is capable of reducing cholesteryl and blood fat and reducing serum and fat accumulation in tissues. When fat is excessive, the preparation is capable of increasing the speed of fat combustion, stimulating intestinal peristalsis, loosening bowels and relieving constipation, so the preparation is capable of effectively reducing weight and shaping figure. The preparation has the advantages of safety, no toxicity, weight reduction for human bodies and no obvious damage to human health.
Thirty patients, 18 females and 12 males, were included who had Class I malocclusion with moderate mandibular crowding and an average age was 19.23 ± 3.1years.They were randomly divided into two parallel groups; a control group without laser intervention and a laser group which received LLLT. All patients followed a non-extraction approach using one category of fixed appliance and matching conventional NiTi archwire sequence during 3 months observation period. In laser group, mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5J/cm2energy density, for 10 seconds at 10 points (0.2 J/point) on facial and lingual aspects. This protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months. In both groups, relief of mandibular crowding was assessed by Little's irregularity index (LII) after 4 weeks (T1), after 8 weeks (T2), and after 12 weeks (T3) intervals. Changes in LII scores were evaluated through scanned 3D models via software. In addition, the monthly rate of OTM was calculated and compared. The level of significance was set at p ≤ 0.05.
FIELD: medicine, surgery, dermatology, obstetrics, gynecology, otorhinolaryngology. SUBSTANCE: the present innovation deals with preparations of antimicrobial action upon purulent-inflammatory processes in soft tissues. It is developed new antiseptic preparation as sodium hypochlorite based upon aerosil-glycerol. New medicinal preparation is obtained at its constant and gradual releasing in the wound, thus, to prolong its antimicrobial action. EFFECT: higher efficiency. 1 ex, 1 tbl
Disclosed is a porous titanium oxide improved in ultraviolet protection ability, usability and transparency in the visible region.  Also disclosed is a method for producing such a porous titanium oxide.  The porous titanium oxide is obtained by adding an alkali into a titanium salt solution containing a polyhydric alcohol, and then heating and hydrolyzing the resulting.  After addition of an alkali, an acid may be further added thereto and then the resulting is heated and hydrolyzed.  Alternatively, after the heating and hydrolysis, the resulting may be subjected to a heat treatment with an acid.  The porous titanium oxide has an average particle diameter of 0.01-1.0 μm and a specific surface area of not less than 50 m2/g.
Tafenoquine (2 x 100 mg tablets) will be self-administered orally with food on Days 1, 2, 3, 4, then weekly thereafter for a total 12-week treatment period. Weekly treatment will start on Day 11 and end on Day 89.
BACKGROUND: Stem cell transplantation shows great potential to improve the long-term survival of cirrhosis patients. However, therapeutic effects may not be homogeneous across the whole study population. This study constructed an easy-to-use nomogram to improve prognostic prediction and aid in treatment decision making for cirrhotic patients.
METHODS: From August 2005 to April 2019, 315 patients with decompensated cirrhosis receiving autologous peripheral blood stem cell (PBSC) transplantation were enrolled in this study. They were randomly classified into training (2/3) and validation (1/3) groups. A predictive model was developed using Cox proportional hazard models and subsequently validated. The predictive performance of the model was evaluated and also compared with other prognostic models.
RESULTS: Age, creatinine, neutrophil-to-lymphocyte ratio, and Child-Turcotte-Pugh class were included in the nomogram as prognostic variables. The nomogram showed high discrimination power concerning the area under receiver operating characteristic curves (3/5-year AUC: 0.742/0.698) and good consistency suggested by calibration plots. Patients could be accurately stratified into poor- and good-outcome groups regarding liver-transplantation free survival after receiving PBSC therapy (P < 0.001). Compared with poor-outcome group, the liver function of patients listed for liver transplantation in the good-outcome group was significantly improved (P < 0.001). Besides, our nomogram achieved a higher C-index (0.685, 95% CI 0.633-0.738) and better clinical utility compared with other conventional prognostic models.
CONCLUSIONS: The proposed nomogram facilitated an accurate prognostic prediction for patients with decompensated cirrhosis receiving PBSC transplantation. Moreover, it also held the promise to stratify patients in clinical trials or practice to implement optimal treatment regimens for individuals.
TB is common in resource-limited countries, and people infected with HIV are especially at risk for TB infection. The antituberculous drug RIF lowers plasma concentrations of PIs by increasing the activity of enzymes responsible for PI breakdown. RIF has been shown to reduce PI effectiveness, a particular concern for HIV infected patients who are also being treated for TB. RTV has been shown to delay the plasma clearance of ATV and increase the plasma half-life of ATV. This study will evaluate the safety, tolerability, and pharmacokinetic (PK) interactions of RTV-boosted ATV, taken concurrently with RIF in HIV uninfected people.

Medical and medication history, a complete physical exam, blood collection, and an electrocardiogram (ECG) will occur at screening. Participants will be enrolled in this study for 41 to 58 days; there will be 3 dosing periods. From Days 1 to 8, participants will receive 600 mg RIF every 24 hours. From Days 9 to 19, participants will receive 300 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours. From Days 20 to 27, participants will receive 400 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours. Study visits will occur at entry; at Days 5, 8, 11, 14, 19, 23, and 27; and at an additional visit between Days 41 and 48. Blood and urine collection will occur at all visits. A targeted physical exam, an ECG, and blood collection for PK analysis will occur at Days 8, 19, and 27.
A cosmetic sampler (Figure 1) formed by screen printing a slurry (2) of cosmetic powder and solvent onto a paper base (1). To prevent off-set of the cosmetic sample (2) during packaging and handling, a protective thin film overlay (4) is laminated to a perimeter adhesive (3) printed on the paper base (1) around the cosmetic (2). The paper base (1) may be replaced by a pressure sensitive adhesive stock (7, 8) to form a unit dose or single application of a cosmetic that can be applied as a label to any desired surface. In other embodiments, a non-­pressure sensitive removable adhesive (10) is used in a two-layer removable label construction (Figure 3A) or a three-layer coupon construction (Figure 4A). The sampler can also be provided with or without the protective overlay (4) in a simple folded hand-out version or as a pad of cosmetic sampler sheets. The sampler can also be used to provide unit doses or single applications of creams, lipsticks, fragrances, pharmaceuticals, lotions, and other high viscosity, waxy materials.
Every patient of more than 18 years giving birth in the University Hospital of Lille in the absence of significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.) or of infection for HIV, VHB, VHC or if unknown status for HIV, VHB, VHC the day of the childbirth.
The invention relates to a perm agent and a preparation method thereof. The perm agent is prepared from the following raw materials in percentage by weight: 5 to 11 percent of L -cysteamine hydrochloride monohydrate, 3 to 8 percent of ethanolamine, 1 to 5 percent of urea, 1 to 5 percent of propanetriol, 0.05 to 0.3 percent of water-soluble wool fat, 0.05-0.4 percent of water-soluble silicone oil and the balance of purified water. The perm agent and the preparation method thereof provided by the invention have the following beneficial effects: as a feed-grade raw material is used, the production process is safe and pollution-free, and accordingly safety and environment-friendliness of the product are guaranteed from the source, and thus the perm agent has no adverse affects on atmosphere, ecotope and users after being used. The perm agent is colorless and odorless liquid, without being covered by essence, which is added just for embellishment, and no foreign odor residual is caused after perm of hair. The perm effect, especially a hair tail effect, is favorable regardless of any hair quality. Curled hair after perm has elasticity, good luster degree, smooth hair quality and natural curling degree.
Patients in the dexmedetomidine arm will receive a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. The patient's managing physician will have the option of beginning the dexmedetomidine infusion without a bolus in circumstances where the patient's sedation level is adequate at enrollment or in the presence of baseline bradycardia /hypotension. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
Patients with middle or low rectal cancer who have T3-4 and/ or N+ will be included. Patients will receive neoadjuvant chemoradiation in the form of pelvic irradiation by 50.4 thousands grays together with radio sensitization by 5-FU or oxaliplatin, 8 months after completion of neoadjuvant chemoradiation patients will be assessed clinically and radiologically. Complete clinical response is diagnosed if clinically no tumor is felt or just small scar and no tumor appears in MRI. Of these patients who achieve complete clinical response we will pick up cases who have split scar sign in the pelvic MRI. Patients will have total mesorectal excision 8-11 weeks after completion of neoadjuvant chemoradiation and pathologic complete response will be assessed. Correlation will be done between preoperative clinical response and postoperative pathologic response
There are pressure forces applied by the design of the spinal orthosis in changing the biomechanics of the scoliotic spine. In the design of the spinal orthosis designed with the 3-point principle, there is a corrective lateral force applied to the main curvature area and two support forces opposing this force. There are breathing spaces in the back area.
A medical device for predicting a user's future glycemic state includes a memory module, a processor module and a user alert module. The memory module is configured to receive and store a plurality of glucose concentrations as a function of time that were generated by a user's use of a continuous glucose monitor. The processor module is configured to derive first and second glucose prediction equations that are fits to the plurality of glucose concentrations stored in the memory module with the fits being based on first and second mathematical models, respectively. The processor module is also configured to calculate first and second predicted glucose concentrations at a future time using the first and second glucose prediction equations, respectively, and to also calculate an average predicted glucose concentration and a merit index based on the first and second predicted glucose calculations. The processor module is further configured to input the plurality of glucose concentrations as a function of time, the average predicted glucose concentration and the merit index into a trained model (e.g., a Hidden Markov Model) that outputs a set of glucose concentration probabilities for the future time and to then predict the user's future glycemic state based on the set of glucose concentration probabilities. The user alert module is configured to alert the user in a manner dependent on the predicted user's future glycemic state.
The present invention relates to a medication for treating rheumatoid disease, particularly relates to a zuanshanfeng rheumatism oil and its preparation method. The zuanshanfeng rheumatism oil is prepared according to weight ratio of: 1-100 parts of zuanshanfeng, 1-1000 parts of seed fat, also including hippocampi, saussurea, dragon's blood, frankincense, myrrh, safflower etc. the raw material is crushed into coarse powder, and sock solution is obtained by adding 10 parts 99 percents ethanol to socking for 30 days, then the finished product is obtained by mixing sock solution and seed fat according to weight ratio. The seed fat comprises cinnamon oil, clove oil, eucalyptus oil, turpentine oil, holly oil etc. the present invention is characterized by external application. The invention is suitable for rheumatoid arthritis, rheumatoild disease, sore muscle, discomfort caused by insect biting.
The disclosure relates to computer technology for precision diagnosis of various states of genetic material such as a gene sequenced from cell-free DNA in a sample. The state may include a somatic homozygous deletion, a somatic heterozygous deletion, a copy number variation, or other states. A computer system may generate competing probabilistic models that each output a probability that the genetic material is in a certain state. Each model may be trained on a training sample set to output a probability that the genetic material is in a respective state. In some embodiments, the computer system may use various probabilistic distributions to generate the models. For example, the computer system may use a beta-binomial distribution, a binomial distribution, a normal (also referred to as "Gaussian") distribution, or other type of probabilistic modeling techniques.